| 11648444 | 31/03/2025 5:36:36 | | The I SPY2 trial found that the combination of the checkpoint inhibitor durvalumab, the PARP inhibitor olaparib, and the taxane paclitaxel followed by doxorubicin cyclophosphamide as neoadjuvant therapy improved pathologic... | | Город: Другой | подробнее... |
|
